WARRINGTON, Pa., March 25, 2014 /PRNewswire/ -- Discovery
Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology
company dedicated to advancing a new standard in respiratory
critical care, today announced new appointments to the Company's
management team. William C. Roberts
has joined the Company as Vice President, Investor Relations and
Corporate Communications. In addition, John
A. Tattory has been appointed Senior Vice President and
Chief Financial Officer. Both Mr. Roberts and Mr. Tattory will
report to John G. Cooper, President
and Chief Executive Officer.
""Will has a track record of success in broad corporate,
pipeline and product communications and investor relations, and
brings significant experience in pediatric respiratory disease –
all valuable to coalesce our communications strategies so our
customers and stakeholders fully understand the value and vision
of SURFAXIN® (lucinactant) and
AEROSURF®," commented John G.
Cooper, Chief Executive Officer at Discovery Labs. "John has
played a key role in the Company's financial management and has the
strategic insights, business knowledge, and proven leadership
ability that make him well suited to assume the role of Chief
Financial Officer."
Prior to joining the Company, Mr. Roberts spent ten years with
ViroPharma Incorporated (recently acquired by Shire), most recently
serving as Vice President, Corporate Communications, with
responsibility for investor and media relations, patient and
physician advocacy, disease awareness, and commercial support.
His record includes developing award-winning communications
programs such as ViroPharma's investor relations program which won
IR Magazine's 2013 'IR Professional of the Year – Small Cap'
(co-winner: R. Doody) and 'Grand Prix, Best Overall Investor
Relations Program – Small Cap' awards. Previously, Mr.
Roberts spent 12 years with MedImmune Inc. (acquired by AstraZeneca
in 2007)in various scientific and investor relations roles of
increasing responsibility. While at MedImmune, he focused primarily
on pipeline and pediatric respiratory franchise communications,
including the development and launch of Synagis® (palivizumab), a
product approved to help protect premature and high risk infants
from a severe respiratory disease.
Mr. Tattory joined Discovery Labs in 2008 and has served since
then as Vice President, Finance. Mr. Tattory is a Certified Public
Accountant with more than 20 years of finance and accounting
experience, including eight years with Ernst & Young LLP and
eight years with Bristol-Myers Squibb (BMS), where he had
responsibility for the financial management of various domestic and
international BMS pharmaceutical business operations. At
Discovery Labs, he is responsible for the management of the
Company's financial operations and has played a key role in the
Company's financing activities.
ABOUT DISCOVERY LABS
Discovery Laboratories, Inc. is a
specialty biotechnology company focused on advancing a new standard
in respiratory critical care. Discovery Labs' technology
platform includes its novel proprietary KL4 surfactant, a
synthetic, peptide-containing surfactant that is structurally
similar to pulmonary surfactant, and its proprietary drug delivery
technologies being developed to enable efficient delivery of
aerosolized KL4 surfactant and other inhaled therapies.
Discovery Labs' strategy is initially focused on neonatology
and improving the management of respiratory distress syndrome (RDS)
in premature infants. Discovery Labs believes that its RDS product
portfolio has the potential to become the new standard of care for
RDS and, over time, enable the treatment of a significantly greater
number of premature infants who could benefit from surfactant
therapy but are currently not treated.
For more information, please visit the Company's website at
www.Discoverylabs.com.
SOURCE Discovery Laboratories, Inc.